Tumor Immune Response as a Biomarker for Metastasis-Free Survival of Breast Cancer and Immune Checkpoint Inhibition Therapy: A Retrospective Cohort Study.

ABSTRACT:

Background

Breast cancers (BRCs) can be classified into 6 molecular subtypes based on gene expression profiles. Previous research suggests that tumor-infiltrating lymphocytes are associated with metastasis-free survival (MFS) in triple-negative and HER2-overexpressing BRC.

Objectives

Our study aims to investigate further how the immune response (IR) may impact MFS in different molecular subtypes of BRC.

Design

A single hospital-based retrospective cohort study.

Methods

A training series of 327 BRCs was used to identify 297 IR transcripts that were correlated with the T cell-associated CD3D transcript or the B cell-associated CD19 transcript. Using these IR transcripts, each of the 6 molecular subtypes was hierarchically clustered into high and low immune respon

SUBMITTER: Lin CW 

PROVIDER: S-EPMC12375856 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature